Literature DB >> 1655263

Tissue renin-angiotensin systems and their modulation: the heart as a paradigm for new aspects of converting enzyme inhibition.

K Lindpaintner1, D Ganten.   

Abstract

Local tissue-resident renin-angiotensin systems are increasingly recognized as important elements of neurohumoral mediation which may act in concert with, but also independently of, the circulating system. The presence of such a system within the heart is of particular interest; current evidence supporting its existence, functional integration, and physiopathological importance as well as the role which its pharmacological modulation may play are reviewed. The elements of the catalytic cascade, renin, angiotensinogen, and angiotensin-converting enzyme, have all been demonstrated in cardiac tissues; both at the protein level and (with the exception of converting enzyme) with regard to local expression of the respective genes. Modulation of gene expression in response to various perturbations has been demonstrated and may occur independently of the plasma or other tissue renin-angiotensin systems. In isolated hearts the generation of biologically active peptides, angiotensins I and II, has been documented, establishing the capability of this system to act as an independently regulated, functionally integrated catalytic pathway for the production of angiotensin II. Activation of either angiotensinogen to angiotensin I or of angiotensin I to angiotensin II is dose dependently inhibited by the administration of renin inhibitors and converting enzyme inhibitors, respectively. Through specific receptors, present in the heart as in other tissues, angiotensin mediates profound effects on cardiomyocyte function and, as we are beginning to learn, on structure and growth. We now have strong evidence that converting enzyme inhibition at a tissue level may profoundly influence and modulate these actions of the cardiac renin-angiotensin system, particularly in the setting of myocardial ischaemia. This may, in the future, open up new vistas for the application of converting enzyme inhibitors and their indications in a widening spectrum of cardiovascular disorders.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655263     DOI: 10.1159/000174905

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  4 in total

1.  Critical role of the chymase/angiotensin-(1-12) axis in modulating cardiomyocyte contractility.

Authors:  Tiankai Li; Xiaowei Zhang; Heng-Jie Cheng; Zhi Zhang; Sarfaraz Ahmad; Jasmina Varagic; Weimin Li; Che Ping Cheng; Carlos M Ferrario
Journal:  Int J Cardiol       Date:  2018-04-21       Impact factor: 4.164

2.  Possible Mechanisms of Local Tissue Renin-Angiotensin System Activation in the Cardiorenal Metabolic Syndrome and Type 2 Diabetes Mellitus.

Authors:  Melvin R Hayden; Kurt M Sowers; Lakshmi Pulakat; Tejaswini Joginpally; Bennett Krueger; Adam Whaley-Connell; James R Sowers
Journal:  Cardiorenal Med       Date:  2011-07-30       Impact factor: 2.041

3.  A facilitatory effect of anti-angiotensin drugs on vagal bradycardia in the pithed rat and guinea-pig.

Authors:  M Rechtman; H Majewski
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

4.  Angiotensin Converting Enzyme Gene Polymorphism and its Association with Hypertension in South Indian Population.

Authors:  Ipsita Choudhury; R Jothimalar; Arun Kumar Patra
Journal:  Indian J Clin Biochem       Date:  2012-05-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.